Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York.
賓夕法尼亞州韋恩,2024年11月26日(GLOBE NEWSWIRE)——專注於開發免疫炎症性疾病新候選藥物的臨床階段生物製藥公司Aclaris Therapeutics, Inc.(納斯達克股票代碼:ACRS)今天宣佈,Aclaris管理團隊成員將在2024年12月3日星期二下午1點參加派珀·桑德勒第36屆年度醫療保健會議期間的爐邊談話等在紐約,紐約。
A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, . The webcast will be archived for at least 30 days on the Aclaris website.
可以通過Aclaris網站 「投資者」 部分的 「活動」 頁面訪問爐邊聊天的網絡直播,.該網絡直播將在Aclaris網站上存檔至少30天。
About Aclaris Therapeutics, Inc.
關於 Aclaris Therapeutics, Inc
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit .
Aclaris Therapeutics, Inc. 是一家處於臨床階段的生物製藥公司,正在開發一系列新的候選藥物,以滿足缺乏令人滿意的治療選擇的免疫炎性疾病患者的需求。該公司擁有多階段候選藥物組合,由探索蛋白激酶調節的強大研發引擎提供支持。如需更多信息,請訪問。
Aclaris Therapeutics Contact:
Aclaris 治療聯繫人:
investors@aclaristx.com
investors@aclaristx.com